J
John T. Brooks
Researcher at Centers for Disease Control and Prevention
Publications - 257
Citations - 24952
John T. Brooks is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 71, co-authored 241 publications receiving 21084 citations. Previous affiliations of John T. Brooks include Emory University.
Papers
More filters
Journal ArticleDOI
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Michael C. Thigpen,Poloko Kebaabetswe,Lynn A. Paxton,Dawn K. Smith,Charles E. Rose,Tebogo M. Segolodi,Faith L. Henderson,Sonal R Pathak,Fatma A. Soud,Kata Chillag,Rodreck Mutanhaurwa,Lovemore Ian Chirwa,Michael Kasonde,Daniel Abebe,Evans Buliva,Roman Gvetadze,Sandra H. Johnson,Thom Sukalac,Vasavi Thomas,Clyde E. Hart,Jeffrey A. Johnson,C. Kevin Malotte,Craig W. Hendrix,John T. Brooks +23 more
TL;DR: Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults and had a significant decline in bone mineral density, which remains unknown.
DatasetDOI
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
TL;DR: The most recent version of the guidelines for the prevention and treatment of opportunistic infections (OI) in HIV-infected adults and adolescents was published in 2002 and 2004, respectively as mentioned in this paper.
Journal ArticleDOI
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Frank J. Palella,Rose K. Baker,Anne C. Moorman,Joan S. Chmiel,Kathleen C. Wood,John T. Brooks,Scott D. Holmberg +6 more
TL;DR: Although overall death rates remained low through 2004, the proportion of deaths attributable to non- AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies.
Journal ArticleDOI
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more
TL;DR: The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.
Journal ArticleDOI
Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992–2003
Pragna Patel,Debra L. Hanson,Patrick S. Sullivan,Richard M. Novak,Anne C. Moorman,Tony C. Tong,Scott D. Holmberg,John T. Brooks +7 more
TL;DR: The incidence of many types of non-AIDS-defining cancer was higher among HIV-infected persons than among the general population from 1992 to 2003, and lower ascertainment of cancer in the HIV cohorts may result in a potential bias to underestimate rate disparities.